Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

sed Consolidated Financial Statements

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands except per share amounts)

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues $ -- $1,102

Operating expenses

Research and development (1) 6,009 6,698

General and administrative 2,045 2,119

Total operating expenses (2) 8,054 8,817

Interest income and other, net 610 1,032

Net loss (2) $(7,444) $(6,683)

Net loss per share, basic and diluted (2) $(0.26) $(0.23)

Share used in calculating net loss per share,

basic and diluted 28,697 28,620

(1) Includes $46 and $275 as an offset in research and development

expense, which represents an estimate of the net reimbursement by

Novartis of ANA975 research and development costs for the three months

ended March 31, 2008 and 2007, respectively.

(2) Includes non-cash operating expenses of $661 and $1,089 determined in

accordance with Statement of Financial Accounts Standards No. 123(R),

"Share-Based Payment" (SFAS No. 123(R)) or approximately $0.02 and

$0.04 effect on basic and diluted net loss per common share for the

three months ended March 31, 2008 and 2007, respectively. Research

and development expense and general and administrative expense

includes $310 and $351 of non-cash operating expenses determined in

accordance with SFAS No. 123(R) fo
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... CHICAGO , May 27 Celsis International, ... its Drug Master Files with the U.S. Food & Drug Administration (FDA) ... solutions and finished goods on the Celsis system. , ... "A growing number of our Rapid Detection customers ...
... Genetics Corporation announced today treatment of the first patient in a nationwide ... have successfully undergone pancreatic surgical resection. , ... "This pivotal study represents one of the largest Phase ... the United States ," said Charles Link , M.D., chairman and ...
... , May 27, 2010 , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical ... Cordis ... launch of the,ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology ...
Cached Biology Technology:Celsis Rapid Detection's Updated Drug Master Files (DMFs) Accepted by FDA 2NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer 2NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer 3NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer 4CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... climate change, a new book by Claire L. Parkinson, ... Center in Greenbelt, Md., can provide some answers. ... Beware the Big Fix," will be published this week ... warming is such a big deal, summarizes 4.6 billion ...
... the Carnegie Institution,s Department of Global Ecology, is among ... the humanities and the arts, business, public affairs, and ... new class of members of the American Academy of ... most prestigious honorary societies, cited Field for his research ...
... pain (or lumbago) is a common ailment often triggered by something ... to remedy the situation? An exercise machine designed specifically for back ... in the Journal of the American College of Sports Medicine ... help the development and endurance of back muscles, you must focus ...
Cached Biology News:NASA scientist publishes new book: 'Coming Climate Crisis? Consider the Past, Beware the Big Fix' 2Carnegie's Chris Field elected to American Academy of Arts & Sciences 2Exercise therapy for low back pain 2